中枢神経系活性多剤併用療法を伴うメディケア薬物療法管理プログラム登録者の特性評価
Anna Hung1,2,3, Lauren E Wilson1, Valerie A Smith1,4,5
1Department of Population Health Sciences, Duke University School of Medicine, Durham, NC.
Journal of managed care & specialty pharmacy
|December 24, 2025
まとめ
メディケアパートD薬物療法管理(MTM)登録者の10%以上が中枢神経系(CNS)活性多剤併用療法を受けている。これらの個人は、男性で、重複して登録されていることが多く、併存疾患や医療利用率が高いため、個別化された介入が必要である。
科学分野:
- 老年薬学
- 医療サービス研究
- 公衆衛生
背景:
- メディケアパートD薬物療法管理(MTM)は、高齢者の薬剤関連問題を軽減することを目的としています。
- 中枢神経系(CNS)活性多剤併用療法は、高齢者の認知機能障害や転倒に関連する重大な懸念事項です。
- MTM登録者におけるCNS活性多剤併用療法の有病率と特性に関するデータは限られています。
主な方法:
- 2019年から2021年までのメディケア5%出来高払いデータと、2020年から2021年のMTMデータを連携させた横断的観察研究を利用しました。
- 患者の特性とMTMサービス利用を、CNS活性多剤併用療法のある登録者とない登録者の間で分析・比較しました。
結論:
- CNS活性多剤併用療法は、MTM登録者の10人に1人以上に影響を与えており、これは一般的なメディケア受益者の割合を超えています。
- これらの登録者は複雑な臨床的および社会経済的ニーズを抱えており、専門的なMTM介入が必要です。
- この脆弱な集団におけるCNS活性多剤併用療法に関連するリスクを軽減するためには、CMRへの参加を増やすことが不可欠です。
さらに関連する動画
関連する概念動画
Drug Therapy
229
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
229
Drug Dosing: Geriatric Patients
206
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
206
Therapeutic Drug Monitoring: Overview and Classification
264
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
264
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
503
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
503
Therapeutic Drug Monitoring: Affecting Factors
170
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
170
Parkinson's Disease: Treatment
933
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
933


